NCT02418104View on ClinicalTrials.gov

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

PHASE1CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Immunity, Humoral
Interventions
DRUG

CHS-1701

DRUG

Pegfilgrastim (Neulasta)

Trial Locations (4)

Unknown

Vince & Associates Clinical Research, Overland Park

Medpace, Cincinnati

ICON, San Antonio

Spaulding Clinical, West Bend

Sponsors
All Listed Sponsors
lead

Coherus Oncology, Inc.

INDUSTRY